0000064803-21-000019.txt : 20210517 0000064803-21-000019.hdr.sgml : 20210517 20210517164041 ACCESSION NUMBER: 0000064803-21-000019 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20210513 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210517 DATE AS OF CHANGE: 20210517 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CVS HEALTH Corp CENTRAL INDEX KEY: 0000064803 STANDARD INDUSTRIAL CLASSIFICATION: RETAIL-DRUG STORES AND PROPRIETARY STORES [5912] IRS NUMBER: 050494040 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-01011 FILM NUMBER: 21931551 BUSINESS ADDRESS: STREET 1: ONE CVS DR. CITY: WOONSOCKET STATE: RI ZIP: 02895 BUSINESS PHONE: 4017651500 MAIL ADDRESS: STREET 1: ONE CVS DR. CITY: WOONSOCKET STATE: RI ZIP: 02895 FORMER COMPANY: FORMER CONFORMED NAME: CVS CAREMARK CORP DATE OF NAME CHANGE: 20070509 FORMER COMPANY: FORMER CONFORMED NAME: CVS/CAREMARK CORP DATE OF NAME CHANGE: 20070322 FORMER COMPANY: FORMER CONFORMED NAME: CVS CORP DATE OF NAME CHANGE: 19970128 8-K 1 cvs-20210513.htm 8-K cvs-20210513
0000064803false00000648032021-05-132021-05-13

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):May 17, 2021(May 13, 2021)
cvs-20210513_g1.jpg
CVS HEALTH CORPORATION
(Exact name of registrant as specified in its charter)
Delaware001-0101105-0494040
(State or other jurisdiction of incorporation)(Commission
File Number)		(IRS Employer
Identification No.)

One CVS Drive, Woonsocket, Rhode Island        02895
(Address of principal executive offices)            (Zip Code)

Registrant’s telephone number, including area code:         (401) 765-1500
Former name or former address, if changed since last report:    N/A

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.01 per shareCVSNew York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐




Section 5 - Corporate Governance and Management

Item 5.07 Submission of Matters to a Vote of Security Holders.
The following are the voting results on each matter submitted to the stockholders of CVS Health Corporation (the “Company”) at the Annual Meeting of Stockholders held on May 13, 2021 (the “Annual Meeting”). The proposals below are described in detail in the proxy statement filed by the Company on April 2, 2021 (the “Proxy Statement”). There were present at the Annual Meeting, in person or by valid proxy, the holders of 1,125,585,859 shares of the Company’s common stock, constituting a quorum.
At the Annual Meeting, 13 nominees for director were elected to the Company’s Board of Directors for a term of one year (Item 1). The Company proposal regarding the ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for 2021 (Item 2) was approved. The Company proposal to approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement (Item 3) was approved. Two stockholder proposals (Items 4 and 5) were not approved.

ItemForAgainstAbstainedBroker Non-Votes
1.The election, for one-year terms, of persons nominated for election as directors of the Company, as set forth in the Company’s Proxy Statement, was approved by the following votes:
Fernando Aguirre938,497,569 6,752,228 1,739,933 178,596,129 
C. David Brown II886,622,076 58,658,214 1,709,440 178,596,129 
Alecia A. DeCoudreaux940,348,495 5,023,246 1,617,989 178,596,129 
Nancy-Ann M. DeParle938,644,542 6,939,966 1,405,222 178,596,129 
David W. Dorman820,655,573 122,465,159 3,868,998 178,596,129 
Roger N. Farah925,968,715 19,296,491 1,724,524 178,596,129 
Anne M. Finucane920,718,682 24,829,190 1,441,858 178,596,129 
Edward J. Ludwig936,314,128 9,069,809 1,605,793 178,596,129 
Karen S. Lynch935,515,848 10,201,413 1,272,469 178,596,129 
Jean-Pierre Millon917,470,260 27,849,807 1,669,663 178,596,129 
Mary L. Schapiro940,106,110 5,462,954 1,420,666 178,596,129 
William C. Weldon925,386,817 19,991,798 1,611,115 178,596,129 
Tony L. White920,006,541 25,203,666 1,779,523 178,596,129 
2.Company proposal to ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for 2021, as set forth in the Company’s Proxy Statement, was approved by the following vote:1,100,737,544 22,778,126 2,070,189 None
3.Company proposal to approve, on an advisory basis, the compensation of the Company’s named executive officers, as set forth in the Company’s Proxy Statement, was approved by the following vote:851,824,270 91,423,549 3,741,911 178,596,129 
4.Stockholder proposal for reducing the ownership threshold to request a stockholder action by written consent, as set forth in the Company’s Proxy Statement, was not approved by the following vote:350,325,582 592,589,356 4,074,792 178,596,129 
5.Stockholder proposal regarding the Company’s independent Board Chair, as set forth in the Company’s Proxy Statement, was not approved by the following vote:233,712,651 709,182,656 4,094,423 178,596,129 
1

Section 9 - Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits.

(d)        Exhibits.

The exhibit to this Current Report on Form 8-K is as follows:

INDEX TO EXHIBIT
104Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CVS HEALTH CORPORATION
Date: May 17, 2021By:/s/ Colleen M. McIntosh
Colleen M. McIntosh
Senior Vice President, Corporate Secretary
and Chief Governance Officer


 EX-101.SCH 2 cvs-20210513.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 cvs-20210513_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Document Type Document Type Entity Address, Postal Zip Code Entity Address, Postal Zip Code Local Phone Number Local Phone Number Written Communications Written Communications City Area Code City Area Code Amendment Flag Amendment Flag Title of 12(b) Security Title of 12(b) Security Entity Address, State or Province Entity Address, State or Province Security Exchange Name Security Exchange Name Soliciting Material Soliciting Material Document Period End Date Document Period End Date Entity Address, City or Town Entity Address, City or Town Entity Tax Identification Number Entity Tax Identification Number Cover [Abstract] Cover [Abstract] Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Pre-commencement Tender Offer Entity Address, Address Line One Entity Address, Address Line One Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Emerging Growth Company Entity Registrant Name Entity Registrant Name Entity File Number Entity File Number Entity Central Index Key Entity Central Index Key Trading Symbol Trading Symbol EX-101.PRE 4 cvs-20210513_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 5 cvs-20210513_g1.jpg CVS HEALTH LOGO begin 644 cvs-20210513_g1.jpg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cvs-20210513_htm.xml IDEA: XBRL DOCUMENT 0000064803 2021-05-13 2021-05-13 0000064803 false 8-K 2021-05-13 CVS HEALTH CORP DE 001-01011 05-0494040 One CVS Drive Woonsocket RI 02895 401 765-1500 false false false false Common Stock, par value $0.01 per share CVS NYSE false XML 7 R1.htm IDEA: XBRL DOCUMENT v3.21.1
Cover Page
May 13, 2021
Cover [Abstract]  
Document Type 8-K
Document Period End Date May 13, 2021
Entity Registrant Name CVS HEALTH CORP
Entity Central Index Key 0000064803
Amendment Flag false
Entity Incorporation, State or Country Code DE
Entity File Number 001-01011
Entity Tax Identification Number 05-0494040
Entity Address, Address Line One One CVS Drive
Entity Address, City or Town Woonsocket
Entity Address, State or Province RI
Entity Address, Postal Zip Code 02895
City Area Code 401
Local Phone Number 765-1500
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.01 per share
Trading Symbol CVS
Security Exchange Name NYSE
Entity Emerging Growth Company false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 1 96 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Page Sheet http://www.cvshealth.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports cvs-20210513.htm cvs-20210513.xsd cvs-20210513_lab.xml cvs-20210513_pre.xml cvs-20210513_g1.jpg http://xbrl.sec.gov/dei/2020-01-31 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "cvs-20210513.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "cvs-20210513.htm" ] }, "labelLink": { "local": [ "cvs-20210513_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "cvs-20210513_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "cvs-20210513.xsd" ], "remote": [ "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "cvs", "nsuri": "http://www.cvshealth.com/20210513", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20210513.htm", "contextRef": "i77c622ca9b9744e7af9556c57fa8000e_D20210513-20210513", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://www.cvshealth.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20210513.htm", "contextRef": "i77c622ca9b9744e7af9556c57fa8000e_D20210513-20210513", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 14 0000064803-21-000019-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000064803-21-000019-xbrl.zip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end